Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
EyePoint Begins Phase 3 LUCIA Trial for Wet AMD
EyePoint Pharmaceuticals has successfully dosed the first patient in the LUCIA trial, marking the start of the company’s second global Phase 3 clinical study for Duravyu (formerly EYP-1901), an investigational sustained-release therapy for wet age-related macular degeneration (wet AMD). Duravyu:…
Nicox Completes Denali Phase 3 Enrollment
Nicox has announced the completion of patient enrollment in China for the Denali Phase 3 trial, which evaluates the efficacy and safety of NCX 470 in patients with open-angle glaucoma or ocular hypertension. The screening process in China is now…
Prevent Blindness Offers GA Educational Materials
Prevent Blindness, a leading nonprofit organization dedicated to eye health, has announced its fourth annual Geographic Atrophy (GA) Awareness Week, taking place from December 2–8, 2024. Geographic Atrophy, an advanced form of dry age-related macular degeneration (AMD), affects an estimated…
AOAExcel Endorses Barti Software as First Eye Care EHR
AOAExcel, a for-profit subsidiary and member-benefit arm of the American Optometric Association (AOA), has announced its first-ever endorsement of an Electronic Health Records (EHR) system—Barti Software. This partnership includes a financial investment in the San Francisco-based EHR provider, marking a…
J&J Names Shawn Millerick Vision Care President
Johnson & Johnson has announced the appointment of Shawn Millerick as the new President of Vision Care, Americas, effective November 11, 2024. In his new role, Mr. Millerick will oversee the strategy and growth of Johnson & Johnson’s Vision Care…
Avirmax Launches ABI-110 Gene Therapy Trial for Wet AMD
Avirmax Biopharma has reached a major milestone in its mission to revolutionize the treatment of wet age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) by successfully dosing the first patient in the phase I/IIa clinical trial of ABI-110, the…
NHS Launches OCT Scans for Diabetic Eye Care
The National Health Service (NHS) England is launching a nationwide program to make optical coherence tomography (OCT) scans more accessible, aiming to improve outcomes for patients with diabetic retinopathy. This initiative will bring advanced imaging technology closer to home for…
Ocular Pain in DED: Insights from the Tibetan Plateau
A recent Chinese study has shed light on the prevalence and influencing factors of ocular pain in individuals suffering from dry eye disease (DED) residing at high altitudes on the Tibetan Plateau. Co-authored by Peng-Cheng Zhang, MD, PhD, and Wen-Shan…
CHMP Endorses FYB203: Aflibercept Biosimilar Approval
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for the marketing authorization of FYB203, a biosimilar candidate to aflibercept. This development marks a significant milestone in expanding affordable…
Adverum Shares Positive Ixo-vec Results for Wet AMD
Adverum Biotechnologies has released promising 52-week topline results from its Phase 2 LUNA trial and new 4-year data from the Phase 1/2 OPTIC study for its gene therapy candidate Ixo-vec (AAV.7m8-aflibercept), targeting wet age-related macular degeneration (AMD). Transformative Potential of…